Lynk Pharmaceuticals Announced First Rheumatoid Arthritis Patient Dosed in Phase Ⅲ Clinical Study of LNK01001
Lynk Pharmaceuticals Co., Ltd. (hereinafter referred to as ‘Lynk Pharmaceuticals’), an innovative clinical stage company, announced that it has dosed the first patient with Rheumatoid Arthritis (RA) in a Phase Ⅲ clinical trial of its highly selective JAK1 inhibitor LNK01001….
Long-term implications of arthritis if left untreated
The author of this article is Dr. Chethana D, Consultant – Rheumatology, Aster CMI Hospital, Bangalore Rheumatoid Arthritis (RA) is a chronic inflammatory disease wherein your immune system mistakenly attacks healthy tissues of the body causing inflammation. In RA, joints…
